IN2014DN05972A - - Google Patents

Info

Publication number
IN2014DN05972A
IN2014DN05972A IN5972DEN2014A IN2014DN05972A IN 2014DN05972 A IN2014DN05972 A IN 2014DN05972A IN 5972DEN2014 A IN5972DEN2014 A IN 5972DEN2014A IN 2014DN05972 A IN2014DN05972 A IN 2014DN05972A
Authority
IN
India
Prior art keywords
diseases associated
present
glucose metabolism
therapeutic agent
abnormal glucose
Prior art date
Application number
Other languages
English (en)
Inventor
Ichiro Hisatome
Shunsuke Tsujimoto
Takashi Shirakura
Shinya Hiramitsu
Original Assignee
Teijin Pharma Ltd
Nat Univ Corp Tottori Univ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teijin Pharma Ltd, Nat Univ Corp Tottori Univ filed Critical Teijin Pharma Ltd
Publication of IN2014DN05972A publication Critical patent/IN2014DN05972A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/4261,3-Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IN5972DEN2014 2012-01-27 2013-01-25 IN2014DN05972A (enExample)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2012015351 2012-01-27
PCT/JP2013/051627 WO2013111870A1 (ja) 2012-01-27 2013-01-25 糖尿病の治療薬

Publications (1)

Publication Number Publication Date
IN2014DN05972A true IN2014DN05972A (enExample) 2015-06-26

Family

ID=48873581

Family Applications (1)

Application Number Title Priority Date Filing Date
IN5972DEN2014 IN2014DN05972A (enExample) 2012-01-27 2013-01-25

Country Status (15)

Country Link
US (1) US20150005506A1 (enExample)
EP (1) EP2808018B1 (enExample)
JP (1) JP5924699B2 (enExample)
KR (1) KR20140134266A (enExample)
CN (1) CN104066430A (enExample)
AR (1) AR089812A1 (enExample)
AU (1) AU2013212865A1 (enExample)
BR (1) BR112014017902A2 (enExample)
CA (1) CA2862602A1 (enExample)
HK (1) HK1201209A1 (enExample)
IN (1) IN2014DN05972A (enExample)
MX (1) MX2014008484A (enExample)
RU (1) RU2014134845A (enExample)
TW (1) TW201334779A (enExample)
WO (1) WO2013111870A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104628673A (zh) * 2015-02-10 2015-05-20 佛山市赛维斯医药科技有限公司 一类含叔丁基脒结构的腈基苯噻唑羧酸酰胺类化合物及用途
CN104628671B (zh) * 2015-02-10 2016-04-13 佛山市赛维斯医药科技有限公司 含苯基脒结构的硝基苯噻唑羧酸酰胺类化合物及用途
CN104610190B (zh) * 2015-02-10 2016-08-17 佛山市赛维斯医药科技有限公司 一类含环丙基脒结构的卤代苯基噻唑羧酸酰胺类化合物及用途
CN104610188B (zh) * 2015-02-10 2016-07-27 佛山市赛维斯医药科技有限公司 含苯基脒结构的腈基苯噻唑羧酸酰胺类化合物、其制备及用途
CN104628672A (zh) * 2015-02-10 2015-05-20 佛山市赛维斯医药科技有限公司 一类含苯基脒结构的烷氧苯基噻唑羧酸酰胺类化合物及用途
KR102473677B1 (ko) * 2015-08-17 2022-12-02 삼성디스플레이 주식회사 액정 표시 장치
ES2842577T3 (es) 2016-02-19 2021-07-14 Nezu Life Science Co Ltd Fármaco terapéutico o profiláctico para la demencia

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE122008000051I1 (de) * 1990-11-30 2009-02-05 Teijin Ltd 2-arylthiazolderivat sowie dieses enthaltendes arzneimittel
HUP9902721A2 (hu) * 1997-11-25 1999-12-28 The Procter & Gamble Co. Tömény textillágyító készítmény és ehhez alkalmazható magas telítetlenségű textillágyító vegyület
US20050074442A1 (en) * 2002-03-13 2005-04-07 Natarajan Ranganathan Compositions and methods for augmenting kidney function
EP1778261A4 (en) * 2004-07-21 2010-08-11 Univ Florida COMPOSITIONS AND METHODS FOR TREATMENT AND DIAGNOSIS OF INSULIN RESISTANCE
AU2006276933A1 (en) * 2005-07-21 2007-02-15 University Of Florida Research Foundation, Inc. Compositions and methods for treatment and prevention of hyperuricemia related health consequences
US20070167454A1 (en) 2005-08-03 2007-07-19 Christopher Lademacher Methods for treating hypertension
JP2009516691A (ja) * 2005-11-21 2009-04-23 タツプ・フアーマシユーテイカル・プロダクツ・インコーポレイテツド Qt間隔延長およびこれに伴う疾病の治療
JP2007210978A (ja) * 2006-02-13 2007-08-23 Hiroshima Univ 耐糖能障害、ii型糖尿病、高脂血症、メタボリックシンドローム、内臓脂肪型肥満、脂肪肝または非アルコール性脂肪性肝炎の予防・治療剤
KR20160031040A (ko) 2006-11-13 2016-03-21 다케다 파마슈티칼스 유에스에이, 인코포레이티드 크산틴 옥시도리덕타아제 억제제를 사용하여 신장 기능을 보존하는 방법
NZ585583A (en) * 2007-11-27 2011-09-30 Ardea Biosciences Inc Novel compounds and compositions and methods of use
PL2266989T3 (pl) * 2008-03-31 2016-04-29 C&C Res Lab Pochodne heterocykliczne
NZ588374A (en) * 2008-04-30 2012-11-30 Wellstat Therapeutics Corp Tetrazole compounds for reducing uric acid
EP2668953A1 (en) * 2008-05-22 2013-12-04 Bristol-Myers Squibb Company Pharmaceutical compositions comprising an SGLT2 inhibitor with a supply of carbohydrate and/or an inhibitor of uric acid synthesis
WO2010045636A1 (en) * 2008-10-19 2010-04-22 Johnson Richard J Therapeutic compositions and methods for treating chronic kidney disease associated with a metabolic imbalance
WO2011022757A1 (en) * 2009-08-24 2011-03-03 Queensland University Of Technology Purine-targeted diagnosis and therapy of wounds
MY167126A (en) * 2010-06-16 2018-08-13 Takeda Pharmaceuticals Usa Inc Novel modified release dosage forms of xanthine oxidoreductase inhibitor or xanthine oxidase inhibitors
CN102958521A (zh) * 2010-06-25 2013-03-06 帝人制药株式会社 缓释性高血压和肾功能不全治疗剂

Also Published As

Publication number Publication date
RU2014134845A (ru) 2016-03-20
JPWO2013111870A1 (ja) 2015-05-11
AR089812A1 (es) 2014-09-17
HK1201209A1 (en) 2015-08-28
BR112014017902A2 (pt) 2017-08-22
AU2013212865A1 (en) 2014-08-14
JP5924699B2 (ja) 2016-05-25
EP2808018B1 (en) 2018-03-14
CA2862602A1 (en) 2013-08-01
US20150005506A1 (en) 2015-01-01
MX2014008484A (es) 2014-10-14
WO2013111870A1 (ja) 2013-08-01
CN104066430A (zh) 2014-09-24
KR20140134266A (ko) 2014-11-21
EP2808018A4 (en) 2015-07-15
EP2808018A1 (en) 2014-12-03
TW201334779A (zh) 2013-09-01

Similar Documents

Publication Publication Date Title
MX2015003594A (es) Agente terapeutico o profilactico para sindrome de lisis tumoral.
IN2015MN00404A (enExample)
MY183312A (en) Pharmaceutical formulation
AU2012214029A8 (en) Rorgammat inhibitors
MX363127B (es) Derivados de benzotiofeno como inhibidores del receptor de estrogeno.
PH12015502839A1 (en) Antiviral compounds
GEP20207105B (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
MX2015005286A (es) Procedimiento para la preparación de derivados del ácido biliar.
PH12017501426A1 (en) Derivatives of betulin
IN2015DN00185A (enExample)
JO3530B1 (ar) مركبات بيريدازين 1،4-ثنائية الإرتباط ونظائرها وطرق معالجة نقص smn وحالاته المرضية.
MX2015010971A (es) Derivado novedoso de pirazol.
IN2014MN02106A (enExample)
AU2012321815A8 (en) 1 - arylcarbonyl - 4 - oxy - piperidine compounds useful for the treatment of neurodegenerative diseases
IN2014DN05972A (enExample)
MY187718A (en) Pharmaceutical formulations
PH12015501752A1 (en) Substituted bisphenyl butanoic phosphonic acid derivatives as nep inhibitors
MX364400B (es) Compuestos de tetraciclina.
WO2011159124A3 (ko) Interleukin-6 억제 작용을 갖는 신규한 벤즈옥사졸 유도체, 이의 제조 방법 및 이를 포함하는 약학적 조성물
MX2021010046A (es) Nueva composicion terapeutica que contiene ingrediente activo de apomorfinas.
WO2011123536A8 (en) Polycyclic tetracycline compounds
NZ711343A (en) Sodium salt of (2s, 5r)-6-benzyloxy-7-oxo-1,6-diaza-bicyclo [3.2.1 ] octane-2-carboxylic acid and its preparation
IN2014CN04449A (enExample)
MY173491A (en) Therapeutic or prophylactic agent for biliary tract diseases
MY164880A (en) Process for the preparation of isoxazolyl-methoxy-nicotinic acids